2.115
1.63%
-0.035
Schlusskurs vom Vortag:
$2.15
Offen:
$2.14
24-Stunden-Volumen:
260.61K
Relative Volume:
0.51
Marktkapitalisierung:
$172.72M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-5.5834
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-2.08%
1M Leistung:
-20.19%
6M Leistung:
+9.59%
1J Leistung:
-2.53%
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.115 | 172.72M | 7.05M | -30.43M | 21.84M | -0.3788 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
2022-02-11 | Herabstufung | Stifel | Buy → Hold |
2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
2021-05-03 | Eingeleitet | Stifel | Buy |
2021-03-25 | Bestätigt | Citigroup | Buy |
2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
2018-11-15 | Eingeleitet | Citigroup | Buy |
2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com
Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com
ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World
ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St
ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World
Leiden-based biotech company ProQR bags €7.7M - Silicon Canals
ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com
JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat
ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance
RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News
ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa
ProQR secures $9.1M for Rett syndrome trial - Investing.com India
ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire
ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan
ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times
ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities - Yahoo Finance
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com - Defense World
OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics NV (MEX:PRQR) Earnings Yield % : N/A% (As of Nov. 21, 2024) - GuruFocus.com
RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ProQR: Q3 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):